Answers are grounded in this paper and cite their sources.
The prevalence of early onset MS (3.6%) in our study confirms the previous findings on early onset MS. A RR course was seen in the majority of cases of early onset MS. A high frequency of relapses, early age at permanent disability, and the presence of malignant cases raise the question of possible early use of disease-modifying therapy in patients with early onset MS.
No takes yet. Share an insight, caveat, or question.
Бойко et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: